You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Precision MRI with a Novel Protein Contrast Agent for Early Detection and Staging of Lung Fibrosis

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: NHLBI

    Summary Lung diseases, such as interstitial lung diseases including idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and acute viral infection are major leading causes of death worldwide. The recent increase due to air pollution, tobacco smoking is and use of E-cigarettes has grown rapidly in the US contributing to a sharp increase in chronic lung diseases. IPF is ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Ultra-low Fouling and Anti-infective and Anti-thrombotic Nitric Oxide Releasing Intravascular Catheters

    SBC: NYTRICX INC            Topic: NHLBI

    Abstract Nytricx is developing a new class of Nitric Oxide (NO)-releasing intravascular medical catheters to combat infection and thrombosis associated with indwelling vascular catheters. NO gas is a natural anti-infective and anti-thrombotic human product principally released from blood vessels and immune cells. Nytricx NO-releasing technology to the catheter surfaces via a polymer matrix, mimics ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within the Skin) patch for the Treatment of Peanut Allergy

    SBC: MOONLIGHT THERAPEUTICS, INC.            Topic: NIAID

    The following contains proprietary/privileged information that Moonlight Therapeutics requests not be released to persons outside the government, except for purposes of review and evaluation Safety and Tolerability of TASIS-Peanut (Targeted Allergen Specific Immunotherapy within theSkin) patch for the Treatment of Peanut Allergy Food allergies affect 30 million people in the USA and 17 million in ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. A Low-Cost Wearable Connected Health Device for Monitoring Environmental Pollution Triggers of Asthma in Communities with Health Disparities

    SBC: WI-SENSE LLC            Topic: NHLBI

    Project Abstract Asthma affects 25 million Americans, and chronic obstructive pulmonary disease (COPD) affects 16 million,together costing 130 billion USD annually to the US healthcare system. Asthma is more prevalent in AfricanAmerican population (10.6%) than white population (7.7%). Poverty level has an impact as well, with twice asmuch asthma incidence in people below 100% of the poverty thresh ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Enhanced renal dialysis membrane performance using lipocalin modified substrates

    SBC: HIBAR Microsciences, LLC            Topic: 400

    PROJECT SUMMARY: It is estimated that more than 30 million American adults have chronic kidney disease (CKD), with nearly 800,000 living with end-stage renal disease (ESRD). People with chronic diseases such as diabetes, high blood pressure, and heart disease are at a higher risk for CKD. Because their kidneys no longer function, individuals with ESRD often rely on hemodialysis to remove waste fro ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Recognition of O-GlcNAc Modified Proteins Using Site-Specific Antibodies

    SBC: GLYCOSCIENTIFIC, L.L.C.            Topic: NHLBI

    Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery) for no apparent reason. PAH is a disease of pulmonary vascular endothelial dysfunction with nitric oxide (NO) deficiency and dysregulated glucose metabolism/utilization. It is a heterogeneous disorder likely to be comprised of overlappi ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. An online professional development course to train CHWs to provide oral health outreach to low-income Black guardians

    SBC: KDH Research & Communication, Inc.            Topic: W

    KDH Research and Communication (KDHRC) submits this Phase II Small Business Innovation Research (SBIR) application to expand and fully evaluate Guardians Receiving Information through Navigators (GRIN). GRIN is a culturally competent, online professional development course to prepare community health workers (CHWs) to provide oral health outreach to low- income Black parents/guardians (henceforth ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a PIV5-based human metapneumovirus (HMPV) vaccine

    SBC: CYANVAC LLC            Topic: NIAID

    ABSTRACT In this Phase I SBIR application, we propose to develop an intranasal, parainfluenza virus 5 (PIV5)-based human metapneumovirus (HMPV) vaccine. HMPV is one of the leading causes of acute respiratory infections (ARIs) in children, immunocompromised individuals, and the elderly. Illness ranges from asymptomatic infection to severe bronchiolitis and pneumonia, with 90-100% of children infect ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Guidewire Design and Coating for Adenosine Delivery

    SBC: ADENOPAINT LLC            Topic: NHLBI

    Coronary artery disease (CAD) effects 14 million Americans resulting in approximately 900,000 myocardial infarction’s (MI) and 650,000 deaths annually. Percutaneous intervention (PCI) is the most frequently performed procedure to treat CAD. Microvascular obstruction (MVO) and “no reflow phenomenon” (NRF) are major barriers that preclude optimal outcomes and are independent risk factors for m ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Design and synthesis of a next generation glycobiology toolbox for cell surface labeling

    SBC: CHEMILY, LLC            Topic: 300

    The cell membrane is the interface by which a cell interacts and communicates with its surroundings, including nearby cells, proteins, and antibodies. Membranes of healthy cells are often modified in diseased states, providing an external means to distinguish between morphologically similar cells. Often, diseased cells display modified carbohydrates and glycans on their cell membranes. Recent deve ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government